Publications by authors named "K Rahbar"
Background: [Lu]Lu-PSMA-617 (Lu-PSMA-617) prolonged life in patients with metastatic castration-resistant prostate cancer (mCRPC) in VISION (NCT03511664). However, distinguishing between patients likely and unlikely to respond remains a clinical challenge. We present the first multivariable models of outcomes with Lu-PSMA-617 built using data from VISION, a large prospective phase 3 clinical trial powered for overall survival.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to compare interim PSMA-PET imaging with post-treatment whole-body scans (WBS) in monitoring treatment response for men with metastasized castration-resistant prostate cancer (mCRPC) undergoing radioligand therapy (RLT).
- Researchers included 188 men and found a strong correlation between responses measured by the two imaging methods, indicating that both affect overall survival (OS) outcomes significantly.
- Results suggested that early treatment responses, particularly a PSA decline of 50% after two cycles, were associated with improved survival probabilities, highlighting the importance of interim imaging in therapy monitoring.
Background And Objective: The prognostic value of declining prostate-specific antigen (PSA) levels is under investigation in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) receiving PSMA-targeted radioligand therapy with [Lu]Lu-PSMA-617 (Lu-PSMA-617). This post hoc analysis of the phase 3 VISION trial aimed to evaluate associations between PSA decline and clinical and patient-reported outcomes in patients receiving Lu-PSMA-617.
Methods: Of 831 enrolled patients with PSMA-positive progressive mCRPC treated previously with one or more androgen receptor pathway inhibitors and one to two taxanes, 551 were randomised to Lu-PSMA-617 plus protocol-permitted standard of care (SoC).
Purpose: This study aims to evaluate the prognostic significance of various previously reported PSMA-PET parameters in patients undergoing Lu-PSMA radioligand therapy (RLT). While individual studies have investigated the prognostic value of one or few of these factors, comprehensive analyses are rare.
Methods: Data of 82 patients undergoing Lu-PSMA-radiologand-therapy (RLT) were analyzed.
Article Synopsis
- Lutetium 177 (Lu-PSMA-617) is a targeted therapy for metastatic castration-resistant prostate cancer (mCRPC), and baseline Ga-PSMA-11 PET/CT parameters may help determine treatment effectiveness.
- The analysis used data from the VISION trial, where participants received either Lu-PSMA-617 plus standard care or standard care alone, focusing on how various PET parameters related to treatment outcomes like survival and response rates.
- Results showed that higher whole-body tumor standardized uptake value (SUV) was linked to better treatment outcomes; for every 1-unit increase in SUV, the risk of radiographic progression and death decreased, indicating Lu-PS